Cristina Larrosa: We recently mapped anti-GD2 mAbs availability worldwide

Cristina Larrosa, Pediatric Oncologist at Sant Joan de Déu Barcelona Hospital, recently posted on LinkedIn:

“We recently mapped anti-GD2 mAbs availability worldwide in our publication “Global Impact of Monoclonal Antibodies (mAbs) in Children: A Focus on Anti-GD2”. AntiGD2 mAbs, the standard of care in high-risk neuroblastoma first-line treatment, are not available in the countries where most children with cancer live.”

Source: Cristina Larrosa/LinkedIn